Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

Eli Lilly and Company’s LLY shares have risen 4.3% since it reported fourth-quarter results on Feb. 6. Lilly’s fourth-quarter ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

“Eli Lilly and Company (NYSE:LLY) is a leading pharmaceutical company that develops diabetes, oncology, immunology and neuroscience medicines. The company generates over half of its revenue in the U.S ...

GLP-1 drugs Mounjaro and Zepbound drive a big revenue increase for the drugmaker Eli ... for Taltz, a psoriasis treatment, and breast-cancer drug Verzenio. Including Thursday's moves, Lilly's ...

Eli Lilly's innovative culture and strong financial ... and Jardiance as well as immunology drug Taltz, cancer drug Verzenio, and Alzheimer's drug Kisunla hold the highest sales potential of ...

Eli Lilly and Company (NYSE ... Jardiance (diabetes and obesity), Taltz (psoriasis), Emgality (migraines), and Verzenio (breast cancer). Shares detracted from performance during the quarter ...

Taltz, Trulicity, Tyvyt and Verzenio) rose 13% to $5.95 billion. Eli Lilly’s new products (products launched since 2022 like Ebglyss, Jaypirca, Mounjaro, Kisunla, Omvoh and Zepbound) contributed ...

Eli Lilly recently said it would post revenue of ... including immunosuppressant Taltz, cancer drug Verzenio, and fast-acting insulin Humalog. And that's before we get into the company's pipeline ...